Simon Burton - Chief Executive Officer David Einhorn - Chairman Neil Greenspan - Chief Financial Officer

Thank you for joining the Greenlight Re Conference Call for the Second Quarter of 2021 Earnings. The company reminds you that forward-looking statements that may be made in this call are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect the company's current expectations, estimates and predictions about future results and events and are subject to risks, uncertainties and assumptions, including those enumerated in the company's Form 10-K from the year end December 31, 2020, and other documents filed by the company with the SEC. If one or more risks or uncertainties materialize, or if the company’s underlying assumptions prove to incorrect, actual results may vary materially from what the company projects. The company undertakes no obligation to update publicly or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as required by law. After the prepared remarks, we will be conducting a question-and-answer session. [Operator Instructions] This call is being recorded. I would now like to turn the conference over to Greenlight Re's CEO, Mr. Simon Burton. Please go ahead, sir.

Good morning, everyone, and thanks for joining today's call. I’d like to start with an overview of the main drivers of financial performance for the second quarter. We saw a small growth in book value per share of 0.8%. We had strong contributions from current year underwriting, share buybacks and of course [ph] valuation of our innovation of investments. These contributions were partly offset by actions taken to strengthen legacy and COVID reserves, and by a small loss in the Solasglas fund. The second quarter adjusted combined ratio which excludes the impact of prior period reserve development and catastrophes was 93%. The differential to the financial quarter result of 96.5% combined ratio is partly due to reserving actions against certain casualty contracts, written between 2014 and 2018 to a single counter party. I’d attribute this development mainly to indications of higher than expected social inflation, although I'm confident that outside of these contracts our exposure to the growing social inflation problem is fairly small. Adjustments to our COVID reserves had a further adverse net financial impact of $3.1 million. The return from innovations investments was $4 million in the second quarter, which represents a 15% increase over the carry values of these investments at March 31. Investor sentiment towards insurer tax continues to be positive and I think there’s every reason to believe that this will continue, at least with respect to businesses that prioritize profitable growth. Many of our partners have taken the practical approach of leveraging parts of traditional distribution networks in combination with unique and disruptive products, and have been quite successful in executing their initial plans. As all of our investment markups have been based on external valuation events, typically in new capital raise, the gains we have recognized to-date are appropriately conservative. Underwriting conditions have…

Thanks, Simon, and good morning everyone. The Solasglas fund returned negative 0.9% in the second quarter. Longs contributed 4.2%, shorts detracted 2.3% and macro detracted 2.4%. During the quarter, the S&P 500 index returned 8.5%. Our long positions in Danimer Scientific and a couple of short positions were our largest detractors. Positive contributors included Long positions in Chemours and CONSOL Energy. After soaring 61% in the first quarter, Danimer stock fell 34% in the second quarter. Despite the volatility in the share price, nothing has changed with respect to our long term investment thesis. We believe the company's IP is significantly more valuable than the entire current market cap of the company, and provides a sizeable margin of safety to our investment. The world is going to want indeed a lot of biodegradable packaging and Danimer's Technology is not easy to replicate. Aside from Danimer, our negative result came in the final two weeks for the quarter, following the FOMC meeting on June 15 and 16. At the meeting the fed acknowledged that the inflation is running harder than expected. This caused some market participants to worry that they may raise rates and begin tapering of asset purchases sooner than the market had anticipated. On the back of this bonds and growth stocks outperformed value stocks dramatically and the stock prices of many of our largest Longs declined. The market appears to believe the fed assertion, that inflationary pressures are not only transitory, but will be diffused quickly, we disagree. While we believe some informational will prove short lived, as bottlenecks related to economic reopening are resolved, we think we have reached a structural change in inflation and expect a period of sustained higher prices. Our largest positions are businesses that should benefit from rising prices in a number of…

Thank you, David, and good morning. Our fully diluted book value per share grew 0.8% during the second quarter, ending the quarter at $13.60 per share. Net income for the quarter was $0.6 million or $0.02 per share. We reported underwriting income of $4.6 million during the quarter and the combined ratio of 96.5%. The quarters underwriting results included $3.6 million of net financial impact from adverse prior year development, which contributed 2.7 points to our combined ratio. Included in the prior year development was $3.1 million of COVID related losses. One point I'd like to emphasize is that the prior year development I just described is on a net financial impact basis. In reviewing our COVID reserves during the quarter, we made adjustments to several accounts and our overall loss estimate changed very little. However, as some of the favorable revisions involved contracts with offsetting profit commissions, the COVID-19 adjustments had an overall negative impact on our underwriting results. Gross written premiums were $141.6 million for the quarter, up 21% from the second quarter of 2020. The bulk of this increase related to Lloyd's multi-line quota share contract. Premium seated were insignificant in the second quarters of 2021 and 2020. Total general and administrative expenses incurred during the quarter were $7.7 million, representing an increase of $1.6 million or 26% from the second quarter of 2020. This increase was driven by the growth of our innovations unit, higher DNO insurance premiums and increased expenses associated with improvements in our information systems and technology. We reported total net investment income of $2 million during the quarter, which includes $4 million of unrealized gains on our innovations investments. We incurred a $2 million loss from our investment in Solasglas during the second quarter. I'll conclude with an update on our share repurchases. During the second quarter we repurchased approximately 700,000 shares at an average price of $9.30 per share, equating to a discount of 32% of our June 30, 2021 fully diluted book value per share. Now, I'll turn the call back to the operator and open it up to questions.

[Operator Instructions] And the first question comes from Kyle LaBarre with Dowling & Partners. Please go ahead.

Great! Thanks. Good morning everybody. First question maybe for Simon. I just appreciate the comments and on social inflation and in your opening remarks and obviously inflation more broadly has been a topical all through earnings, including on the economic side. Just curious in terms of what you're seeing in the portfolio and maybe how the rise in economic inflation is changing your outlook from an underwriting opportunity and reserving perspective.

Yeah, good morning Kyle. Social inflation is only so called social inflation, I'm not sure there's a very clear definition of the term. It’s certainly a growing issue for the industry. We are seeing signs of unanticipated claim inflation on business that is reasonably mature at this point, in our portfolio and I think across the industry. So that's the reason for the uptick in our reserves in a relatively isolated pocket. Across the rest of our reserve block, our portfolio is characterized generally by short to low medium tail liabilities and on the medium tail side, it's more on the workers comp end of things where awards generally are capped and social inflation is less likely to be rampant. So in the context of our portfolio, I'm quite confident that should social inflation take off in the way that the industry fears, that we have this pocket where we've taken some of provision, but elsewhere in the portfolio we feel quite comfortable. More generally, I'd say that in terms of our overall appetite, it is guiding our appetite. We think that the proposition on short to medium tell lines, more on the short tail side for us, given our scale, given our operational reach is tremendously good, and the jeopardy that may come on the longer tail business without the sort of global reach that some of our peers have, is something that we’ve decided not to do.

Got it. No, that's helpful. And one more for me, just again sort of a broader discussion, but obviously we are talking small numbers with the COVID revisions. But I maybe a little more interested in, you know we're a year, year and a half past sort of the start. We start to see losses come through, reserves develop. Has your view on the overall impacts of COVID changed materially and are you seen anything that's been surprising either positive or negative in terms of how it's played out so far.

Sure. So we're not that surprised. Of course there was a relatively small provision this quarter, but it was, it didn't emanate from any particular surprise in the portfolio. I’ll let Neil elaborate in a moment if he wishes. I think from an industry perspective, where we are less, we are less impacted by this, but I think the industry should remain concerned about the impact on excess loss of property cap treaties. I think that is, it seems to be a quite substantial unresolved issue for the industry. Our exposure is quite manageable there. I think it may be more of an issue for other reinsurers.

Hi Kyle, Neil here. Thanks for the question. Not a lot to add. Even, they indicated actually our total ultimate loss on COVID came down a little bid in the quarter. It was just that, it was acquisition cost issue, the profit commission issue which confused things a little. But as Simon indicated, we are not seeing a lot of movement on our end in our notebook.

Perfect! That’s it from me. Thanks very much.

Thanks Kyle.

[Operator Instructions] This concludes our question-and-answer session. Should you have any follow-up questions, please direct them to Adam Prior of the Equity Group Incorporated at 212-836-9606 and he will be happy to assist you. We also remind you that a replay of this call and other pertinent information about Greenlight Re is available at our website at www.greenlightre.com. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.